SYNLAB invests in new, cutting-edge laboratory in Munich and further expands its leading position in the region

• SYNLAB moves to new city centre location at Schwanthalerhöhe in Munich, increases laboratory space to 6,000 square metres and modernises the laboratory equipment
• The move and modernisation will enable SYNLAB to continue its steady growth and fully tap its potential in the region
• With the investment of around 20 million euros, SYNLAB optimises the processing speed in numerous workflows, increasing digitalisation levels and significantly simplifying communication between the 200 employees at the site

SYNLAB, Europe’s leading provider of medical diagnostic services and specialty testing, is further expanding its leading position in southern Germany by investing around 20 million euros in a new, state-of-the-art laboratory location at Schwanthaler Straße 115 in the centre of Munich. Besides the modernisation of the laboratory equipment, SYNLAB also expands its laboratory space at the new location. Thereby, SYNLAB is in a strong position to continue its steady growth path in the region and further expand its leading position. The company has continuously upheld smooth laboratory operations during the relocation and officially inaugurated the new facility at Munich's Theresienwiese in March 2023.

Dr. Olaf Wetlitzky, Medical Director of SYNLAB Labor München Zentrum is very pleased:

“Our core laboratory now has an area of around 6,000 square metres. Having all divisions, including the administration, on one level will significantly improve both the processes in our daily operations as well as the communication among our approximately 200 employees.”

Axel Niedermeyer, Organisational Head of the laboratory, further underlines: “With the relocation, we have upgraded our laboratory to the cutting edge of technology. With our efficient instrumentation, we now achieve a degree of digitalisation of over 70%. As a consequence, we can also further optimise the sample flow. Due to the intense competitive situation in Munich’s laboratory market, this is a real advantage.”

SYNLAB Labor München Zentrum was founded in 1986 and maintains a customer base of over 3,000 medical practices to date. In addition, numerous pharmaceutical and diagnostics companies as well as several private and university clinics benefit from the services of SYNLAB’s experts. The laboratory’s portfolio includes several thousand different tests. 80% of the analyses carried out are completed on the same day.

For more information:

About SYNLAB

• SYNLAB Group (FSE: SYAB, ISIN: DE000A2TSL71) is the leader in medical diagnostic services and specialty testing in Europe. The Group offers a full range of innovative and reliable medical diagnostics to patients, practising doctors, hospitals and clinics, governments and corporates.
• Providing the leading level of service within the industry, SYNLAB is the partner of choice for routine and specialty diagnostics in human and veterinary medicine. The Group continuously innovates medical diagnostic services for the benefit of patients and customers.
• SYNLAB operates in 36 countries across four continents and holds leading positions in most markets, regularly reinforcing the strength of its network through a proven acquisition strategy. More than 28,000 employees, including over 2,000 medical experts, contribute every day to the Group’s worldwide success.
• SYNLAB performed around 600 million laboratory tests and achieved revenues of €3.25 billion in 2022.
• In Germany, SYNLAB employs over 5,000 people at more than 40 laboratory locations.
• More information can be found on www.synlab.de / www.synlab.com.

Forward looking statements

This document does not constitute or form a part of, and should not be construed as, an offer for sale or subscription of or solicitation of any offer to purchase or subscribe for any securities in any jurisdiction.

Statements made in this document may include forward-looking statements. Forward-looking statements include all statements that are not historical facts and can be identified by the use of forward-looking terminology such as the words "believes", "expects”, “expected”, "may", "will", "would", "should", "seeks", "pro forma", "anticipates", "intends", "plans", "estimates", “estimated”, or the negative of any thereof or other variations thereof or comparable terminology, or by discussions of strategy or intentions. These statements are not guarantees of future actions or performance and involve risks, uncertainties and assumptions as to future events that may not prove to be accurate. Actual actions or results may differ materially from what is expressed or forecasted in these forward-looking statements. As a result, these statements speak only as of the date they were made and SYNLAB undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. It should be noted that past performance is not a guide to future performance. Interim results are not necessarily indicative of full-year results.